Clinical Trial: Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07723261) titled 'Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)' on July 20.

Brief Summary: This is multicenter, prospective, open label, non-interventional study that will collect real-world data (RWD) on the clinical efficacy and safety of NalIriFOx as a first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).

Study Start Date: March 30

Study Type: OBSERVATIONAL

Condition: Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Recruitment Status: RECRUITING

Sponsor: Hellenic Cooperative Oncology Group

Published by HT Digital Con...